Zimmer Biomet (NYSE:ZBH) Stock Rating Upgraded by Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

ZBH has been the topic of several other research reports. Barclays lowered their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a report on Wednesday, November 5th. Baird R W lowered Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 16th. Evercore ISI raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. Johnson Rice set a $112.00 price target on Zimmer Biomet in a report on Wednesday, November 5th. Finally, The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $107.33.

Zimmer Biomet Trading Down 1.5%

Shares of Zimmer Biomet stock opened at $87.42 on Friday. Zimmer Biomet has a 1-year low of $85.33 and a 1-year high of $114.44. The company’s fifty day simple moving average is $91.59 and its 200-day simple moving average is $96.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The stock has a market capitalization of $17.32 billion, a PE ratio of 21.64, a P/E/G ratio of 2.23 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.Zimmer Biomet’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period last year, the firm earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current year.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Legacy Wealth Asset Management LLC grew its position in Zimmer Biomet by 2.3% during the third quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after purchasing an additional 106 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Zimmer Biomet by 7.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 111 shares during the period. Cullen Frost Bankers Inc. grew its holdings in shares of Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Generali Asset Management SPA SGR grew its holdings in shares of Zimmer Biomet by 0.9% during the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after acquiring an additional 122 shares in the last quarter. Finally, Brookstone Capital Management increased its stake in shares of Zimmer Biomet by 1.3% in the third quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after acquiring an additional 123 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.